IDO Targeting in Sarcoma: Biological and Clinical Implications

Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy. We recently demonstrated an increase in Kynurenine Pathway (KP) activity in the plasma of sarcoma patients treated with pembrolizumab. While the KP has already been described to favor immune escape...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Immunol
Egile Nagusiak: Nafia, Imane, Toulmonde, Maud, Bortolotto, Doriane, Chaibi, Assia, Bodet, Dominique, Rey, Christophe, Velasco, Valerie, Larmonier, Claire B., Cerf, Loïc, Adam, Julien, Le Loarer, François, Savina, Ariel, Bessede, Alban, Italiano, Antoine
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Immunology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066301/
https://ncbi.nlm.nih.gov/pubmed/32194552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.00274
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak